Nolato AB (publ) (NLTBF)
OTCMKTS
· Delayed Price · Currency is USD
6.00
+1.00 (20.00%)
May 6, 2025, 10:08 AM EDT
Nolato AB Revenue
Nolato AB had revenue of 2.45B SEK in the quarter ending March 31, 2025, with 0.45% growth. This brings the company's revenue in the last twelve months to 9.68B, up 1.71% year-over-year. In the year 2024, Nolato AB had annual revenue of 9.66B with 1.24% growth.
Revenue (ttm)
9.68B SEK
Revenue Growth
+1.71%
P/S Ratio
1.73
Revenue / Employee
1.66M SEK
Employees
5,837
Market Cap
1.66B USD
Revenue Chart
* This company reports financials in SEK.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.66B | 118.00M | 1.24% |
| Dec 31, 2023 | 9.55B | -1.23B | -11.40% |
| Dec 31, 2022 | 10.77B | -836.00M | -7.20% |
| Dec 31, 2021 | 11.61B | 2.25B | 24.05% |
| Dec 31, 2020 | 9.36B | 1.44B | 18.18% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Elite Pharmaceuticals | 70.00M |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
| American Oncology Network | 1.76B |
Nolato AB News
- 4 months ago - Nolato AB (STU:NBF) Q4 2024 Earnings Call Highlights: Strong Profit Growth Amid Sector Challenges - GuruFocus
- 4 months ago - Q4 2024 Nolato AB Earnings Call Transcript - GuruFocus
- 1 year ago - Cyclical Industrials' Turnaround Is Close, Though Nolato Isn't Cheap, It's Still A Buy - Seeking Alpha